What This Bill Does · Plain English
Summary · Congress.gov
Access to Innovative Treatments Act of 2026 This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period. The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.
Frequently Asked Questions
Did HR.9418 pass?
HR.9418 is still alive. Current stage: COMMITTEE. Pass likelihood: pending.
What does HR.9418 do?
Access to Innovative Treatments Act of 2026 This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so. Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period. The bill also prohibits the CMS from applying prior coverage determinations tha…
Who sponsored HR.9418?
HR.9418 was sponsored by Nanette Diaz Barragán (D-California).
Full Bill Text
Full text not yet indexed for this bill. Check Congress.gov for the official text.
Loading intelligence layer…